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ABSTRACT The latent membrane protein 1 (LMP1) of
the Epstein–Barr virus has transforming properties in rodent
fibroblasts and is expressed in most of the cancers associated
with Epstein–Barr virus (EBV) infection including posttrans-
plant lymphomas, Hodgkin’s disease, nasopharyngeal carci-
noma, and AIDS-related lymphomas. In this study, three
lineages of LMP1 transgenic mice were established with LMP1
expressed under the control of the Ig heavy chain promoter
and enhancer. Lymphoma developed in all three lineages, and
the incidence of lymphoma increased significantly with age
with lymphomas developing in 42% of transgenic mice over 18
months. The expression of LMP1 was detected at high levels
in the lymphoma tissues but only at trace levels in normal
lymphoid tissues. Gene rearrangement of the Ig heavy chain
indicated monoclonality or oligoclonality in all lymphomas,
some of the lymphoid hyperplastic spleens, and some histo-
logically normal spleens. These data reveal that LMP1, with-
out the expression of other EBV genes, is oncogenic in vivo and
indicate that LMP1 is a major contributing factor to the
development of EBV-associated lymphomas.
Epstein–Barr virus (EBV) is linked to the development of
several malignancies, primarily of B cell and epithelial-cell
origin, including lymphoma in the immunocompromised host
and nasopharyngeal carcinoma (1). A key biologic property of
EBV that underlies its clear link to cancer is its ability to alter
B cell growth regulation and induce permanent growth trans-
formation. The B cells immortalized in vitro are infected
latently and express at least nine proteins including six Ep-
stein–Barr virus-encoded nuclear antigens (EBNA 1–6), and
three latent membrane proteins (LMP1, LMP2A, and
LMP2B) (2). Among these, only LMP1 can induce morpho-
logic transformation and tumorigenicity in rodent fibroblasts
(3). The expression of LMP1 also induces many changes
associated with B cell activation, including cell clumping,
increased numbers of villous projections, and the increased
expression of CD23, CD39, CD40, CD44, and vimentin as well
as the cell adhesion molecules, lymphocyte function-associated
antigen-1, intercellular adhesion molecule-1, and lymphocyte
function-associated antigen-3 (2). LMP1 also up-regulates
bcl-2 and A20 expression, and this up-regulation, at least in
part, contributes to its protective effect against apoptosis
(4–6).
Recently, LMP1 has been shown to interact with the sig-
naling molecules, tumor necrosis factor receptor-associated
factors (TRAFs), that associate with the family of tumor
necrosis factor receptors (TNFRs) (7). Two hybrid studies first
identified TRAF3 with both LMP1 and CD40 (7, 8). Both the
activation of CD40 and the expression of LMP1 activate
NF-kB and induce the expression of many of the same cellular
genes (5, 9–11). The TRAF interacting domain of LMP1 is
essential for transformation as is the transmembrane region of
LMP1, which is necessary for aggregation in the cellular
membrane (12, 13). These features suggest that LMP1 func-
tions as a constitutively activated member of the family of
TNFRs (14, 15). Members of this family, which includes TNFR
1 and 2, CD40, and Fas(CD95), can either activate cellular
proliferation through the activation of NF-kB (16, 17) or
induce apoptosis through their association with death domain-
containing proteins such as Fas-associating protein with death
domain (FADD) and receptor interacting protein (RIP; ref.
18).
The aberrant expression, activation, or inactivation of crit-
ical cellular regulatory functions such as c-myc, bcl-2, ras, or
p53 have been shown to be oncogenic in transgenic mice and
also to be affected in human tumors (19, 20). Constitutively
activated growth-factor receptors such as erbB also are trans-
forming in vitro and oncogenic in vivo (21). Although the
members of the TNFR family clearly can regulate cellular
growth, constitutively activated forms have not been identified
in tumors. As a novel, constitutively active member of this
family, LMP1 provides a mechanism with which to evaluate the
oncogenic potential of this receptor family.
In this study, we successfully established three lineages that
express LMP1 in B lymphocytes. The transgenic mice have an
increased incidence of lymphoma in mice 1 year or older. In
normal spleens, the protein was detected at very low levels,
whereas in tissues with lymphoma, LMP1 expression was
detected at levels similar to the level in transformed lympho-
cyte lines. This study reveals a high correlation between
expression of LMP1 and the development of lymphoma and
suggests that LMP1 is a critical oncogenic factor in the
development of EBV-associated cancers.
MATERIALS AND METHODS
Construction of Plasmids and Transgenic Mice. The coding
sequences of LMP1 were cloned with the Ig heavy chain (IgH)
promoter and enhancer into the pGEM2 vector (Promega). An
EcoRI-PvuI fragment representing the Ig construct that ex-
presses LMP1 was injected into fertilized oocytes from
(C57BLy6 3 SJL)F1 mice. Founders were crossed initially with
strain C57BLy6 and then crossed with BALByc mice. Animals
were screened for the presence of transgene with Southern
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Blot analysis of tail DNA and hybridization to the XhoI
fragment within LMP1 (22). The transgene copy number was
determined by comparing the intensity of the hybridizing
bands on an autoradiograph with a serial dilution of DNA from
the Raji cell line that has a known copy number of 50 per cell.
Reverse Transcriptase–PCR (RT-PCR) Analysis of LMP1.
RNA and DNA were extracted from frozen-tissue specimens,
and LMP1 specific RNA was analyzed by using an RT-PCR
assay as described (23, 24).
Immunoblot Analyses of LMP1, A20, Bcl-2, and c-Myc.
Frozen tissues were pulverized and resuspended in RIPA
buffer (25 mM Tris, pH 7.5y150 mM NaCly2 mM EDTAy1%
Nonidet P-40y0.5% sodium deoxycholatey0.1% SDSy10 mM
sodium orthovanadatey50 mM NaFy50 mM b-glycerophos-
phatey2 mg/ml aprotininy4 mg/ml leupeptiny3 mg/ml pepsta-
tiny100 mg/ml phenylmethylsulfonyl f luoride) at 4°C. Samples
were centrifuged at 7,500 3 g for 10 min at 4°C, and the
supernatants were collected for immunoblot analysis. Protein
concentrations were determined with a Bradford assay (Bio-
Rad). Protein samples (200 mg) were separated by SDSyPAGE
(8% for A20, 8.5% for LMP1 and c-Myc, and 12% for Bcl-2)
and transferred electrophoretically onto 0.45 mm Optitran
membranes (Schleicher & Schuell). The equal loading of
samples was evaluated by staining the filter with India ink.
LMP1 was identified with the antibodies S12 or CS1–4 (Dako).
Mouse monoclonal anti-A20 (at 1:1000 dilution), rabbit poly-
clonal anti-Bcl-2 (PC68-C; at 1:500 dilution; Calbiochem), and
rabbit polyclonal anti-c-Myc (at 1:500 dilution; Santa Cruz
Biotechnology) were used for A20, Bcl-2, and c-Myc immu-
noblots, respectively. For Bcl-2 immunoblots, a peptide com-
petition assay was performed by incubating anti-Bcl-2 with the
original peptide antigen, PP52 (Calbiochem), used to make the
antibody, at 1:10 (antibody:peptide ratio) overnight at 4°C.
The filters were washed in Tris-buffered saline with 0.5%
Tween-20 three times for 15, 5, and 5 min, respectively. For
LMP1 and A20 blots, the filters were incubated with 1:1,000 of
horseradish peroxidase-conjugated goat anti-mouse k light
chain (Southern Biotechnology Associates) in blocking solu-
tion for 1 hr and washed again with five changes of Tris-
buffered saline with Triton X-100 for 30 min. Horseradish
peroxidase-conjugated anti-rabbit IgG (Amersham) was used
for Bcl-2 and c-Myc blots, at 1:2,000. The filters were then
incubated with SuperSignal Chemiluminescent Substrate for
immunoblotting (Pierce) for 3 min and exposed for autora-
diography.
IgH Gene Rearrangement. Southern blots, prepared with
DNA (8 mg) extracted from tissues and digested with EcoRI,
were hybridized with 32P-labeled single-stranded RNA probe,
PJ11, representing the JH region of the IgH gene (25).
Histopathologic Examination and Immunohistochemical
Staining for LMP1. Tissues were fixed in either 4% parafor-
maldehyde or 10% neutral-buffered formalin, for 12–24 h,
embedded in paraffin, and sectioned 4 mm thick. Tissues were
stained with hematoxylin and eosin for routine histologic
examination. Sections selected for immunostaining were pre-
pared on poly-L-lysine-coated slides, deparaffinized, rehy-
drated, and treated with proteinase K (Dako). The sections
were incubated with a rabbit polyclonal anti-LMP1 (26) that
was preabsorbed three times with crude mouse splenic extracts
for 90 min at room temperature. Sections were incubated with
peroxidase-conjugated goat anti-rabbit antibody (Amersham).
Staining was visualized with diaminobenzidine (Sigma), and
sections were lightly counterstained with methyl green. For
immunofluorescence staining for LMP1, 5 mm frozen sections
were stained with a fluorescein-conjugated goat anti-rabbit
antibody. Fluorescein-conjugated anti-mouse CD3, phyco-
erythrin-conjugated anti-mouse B220 (PharMingen), and tet-
ramethylrhodamine B isothiocyanate-conjugated anti-mouse
IgG (Southern Biotechnology Associates) were used as stain-
ing for T and B lymphocyte markers, respectively.
RESULTS
Production of IgH LMP1 Transgenic Mice. To target LMP1
expression to B cells, a construct was prepared in which the
genomic coding sequence for LMP1 was cloned under the
control of the mouse IgH enhancer and a VH promoter from
a mouse hybridoma. We established four founders of IgH
LMP1 transgenic mice and designated them 3, 6, 8, and 9.
Founder 8 succumbed to lymphoma; therefore, a lineage was
not established. Lineages were established successfully from
founders 3, 6, and 9 with approximately 10 copies of the
transgene in lineage 3, 2 copies in lineage 6, and 5 copies in
lineage 9 (Table 1). The lineages have been maintained as
heterozygous lines with all of the transgene insertions at
autosomal sites. Interestingly, in lineage 3 apparently the
transgene has integrated into the Ig locus. The digestion of
DNA from lineage 3 by restriction enzymes produces two
genomic BamHI fragments of 23 kb and 6.6 kb that hybridize
to the heavy chain Ig joining region and represent the two Ig
alleles. Hybridization with the LMP1 coding sequences also
identified the larger, 23-kb fragment, indicative of insertion
into the Ig locus.
Incidence of Lymphoma. In comparison with negative lit-
termates, lymphoma developed with increased incidence in all
lineages. The development of lymphoma was rare in mice
under 1 year of age but increased to 32% in mice over 1
year-old and to 42% in mice over 18 months (Table 1). The
incidence of lymphoma was higher in lineages 3 and 9 with 42%
and 38% of animals over 12 months and 50% of animals over
18 months developing lymphoma (Table 1). The incidence of
lymphoma in elderly mice in lineages 3 and 9 was statistically
significantly greater than strain- and age-matched negative
transgene controls, housed under the same conditions, and
given the same diet, with P values of 0.0001 and 0.008,
respectively.
Most mice with lymphoma had massive enlargement of the
spleen. In '60% of animals with lymphoma in all three
lineages, the lymphoma was disseminated and frequently
involved the liver, lungs, or the mesenteric, hilar, or cervical
lymph nodes. Lymphoma was found infrequently in the bone
marrow and never detected in the central nervous system. The
lymphomas were predominantly follicular center-cell lym-
phoma with either predominantly large cells or mixed small
and large cells (Fig. 1A). These neoplasms were composed of
intermediate to large, cohesive lymphoid cells with irregularly
shaped oval nuclei and moderate to abundant lightly eosino-
philic cytoplasm. The chromatin was often condensed and
marginated on the nuclear membrane with the nucleoli also
often juxtaposed with the nuclear membrane. Mitotic figures
were observed frequently. In a few animals without frank
Table 1. Increased incidence of lymphoma in transgenic mice
Lineage Copy no.
Age range,
months n %Lymphoma (n)*
3 10 ,12 13 0
12–18 12 41.7 (5)
.18 41 51.2 (21)
6 2 ,12 8 0
12–18 11 18.2 (2)
.18 26 23.1 (6)
9 5 ,12 3 33.3 (1)
12–18 8 37.5 (3)
.18 12 50.0 (6)
Total – ,12 24 4.2 (1)
12–18 31 32.3 (10)
.18 79 41.8 (33)
Control 0 .18 43 11.6 (5)
*Fisher’s exact test indicates P values of 0.0001, 0.31, and 0.008 for
lineages 3, 6, and 9, respectively, compared to negative controls.
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lymphoma, aggressive lymphoid infiltrates that invaded the
adjacent normal tissue were detected (Fig. 1B). These infil-
trates were monoclonal or oligoclonal by Ig gene rearrange-
ment; however, the lymphocytes lacked the enlarged vesicular
nuclei and prominent nucleoli characteristic of tumor cells.
Expression of LMP1. LMP1 expression was analyzed by
RT-PCR amplification of spliced mRNAs, immunoblot anal-
yses, and immunohistochemistry. In almost all tissue samples
from all transgenic animals, including liver, ovary, and intes-
tine, LMP1 expression was detected by RT-PCR (data not
shown). The detection of mRNA did not correlate with LMP1
expression detected on immunoblots nor with evidence of
pathology. As it is unlikely that the IgH promoter and en-
hancer is active in all tissues, the detection of LMP1 transcrip-
tion in tissues likely reflects transcription in infiltrating lym-
phocytes.
Immunohistochemical detection was not possible with the
LMP1 mouse monoclonals; therefore, an LMP1-specific rabbit
antiserum was used. This reagent could weakly detect LMP1
in 60% to 70% of EBV-infected lymphoid cell lines by using a
fluorescein-conjugated goat anti-rabbit secondary antibody
(26). In tissues with lymphoma, LMP1 was detected in a
significant portion of cells with the characteristic capping of
LMP1 in some cells (Fig. 1D), whereas normal rabbit serum
did not stain the lymphoma tissue (Fig. 1E). These same
samples also stained positive for B220 (data not shown) and
cytoplasmic IgG (Fig. 1F), but not CD3, a T cell marker (data
not shown), indicating that the LMP1 was expressed in B cells.
Similarly, LMP1 was detected in membrane patches in a
lymphoid infiltrate with a peroxidase-conjugated goat anti-
rabbit secondary antibody (Fig. 1C). A high level of LMP1 was
also detected by immunoblot analysis of a protein lysate
prepared from this tissue, confirming immunohistochemical
detection.
Immunoblot detection of LMP1 in tissues involved with
lymphoma revealed high levels of expression in all but one
sample examined (Fig. 2). In five occurrences of lymphoid
hyperplasia, where the lymphoid tissue was greatly enlarged
with increased numbers of blast cells and mitotic figures but
the lymphocytes appeared to be nonneoplastic, LMP1 was also
detected but at variable levels (Fig. 2, lanes 6 and 7). LMP1 was
FIG. 1. Histopathology and immunohistochemistry for LMP1 in lymphoma and lymphoid infiltrate. (A) Follicular center cell lymphoma (lineage
3), large cell type. The normal architecture of the spleen is effaced by sheets of large neoplastic cells with abundant cytoplasm. The nuclei are
irregularly shaped, with clumped or marginated chromatin and sometimes prominent nucleoli. Mitotic figures are frequently present. (Hematoxylin
and eosin; 3600.) (B) Lymphoid infiltrate in the lung. An aggressive lymphoid-cell infiltrate (lineage 6) has invaded the adjacent alveolar tissue.
Analysis of DNA extracted from this tissue demonstrated monoclonal heavy chain rearrangement on Southern blot. A high level of LMP1 was
detected by immunoblot analysis of a protein lysate prepared from this tissue. (Hematoxylin and eosin; 3200.) (C) Expression of LMP1 in the
lymphoid infiltrate shown in B. The tissue was stained with rabbit polyclonal anti-LMP1 and detected with an immunoperoxidase-tagged goat
anti-rabbit serum. LMP1 is detected as dark brown staining in the cell membrane, with some cells showing the characteristic capping. (31,000.)
(D and E) Expression of LMP1 in lymphoma tissue and negative-staining control (lineage 3). The splenic lymphoma tissue was stained with either
rabbit polyclonal anti-LMP1 (D) or normal rabbit serum at same dilution (E). The staining was detected with fluorescein-conjugated goat anti-rabbit
antibody. LMP1 is detected as green fluorescence in the plasma membrane, with some cells showing the characteristic capping. (31,000.) (F)
Presence of cytoplasmic Ig in the lymphoma. The same lymphoma tissue depicted in D and E was stained with tetramethylrhodamine B
isothiocyanate -conjugated goat anti-mouse IgG. IgG is detected as red fluorescence in the cytoplasm of most cells. This lymphoma also expresses
a high level of LMP1 and was shown to be monoclonal by IgH gene rearrangement (see also Fig. 4 A and B). (31,000.)
FIG. 2. Levels of the expression of LMP1 correlate with lymphoid
pathologies. Immunoblots were prepared with total protein tissue
lysate (200 mg) and 50 mg of protein lysate from the B95–8 EBV-
positive lymphoid cell line (lane 1) and reacted with the CS1–4 mouse
monoclonal antibody. A spontaneous lymphoma was obtained from a
2-year-old LMP1-negative littermate (lane 2). Lanes 3–5 are lym-
phoma tissues; lanes 6–7 are lymphoid hyperplasia; lanes 8–10 are
normal lymphoid tissues. Lanes 3–10 are transgenic splenic tissues
from lineage 3.
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not detected frequently in normal spleen tissue but was
detected at very low levels in some samples (Fig. 2, lane 10).
The frequency of detection of LMP1 in normal spleens
increased with age. In mice under 12 months, LMP1 was
detected at low levels in 35% of normal spleens, whereas in
mice older than 18 months, LMP1 was detected in 75% of
normal spleens.
Analysis of Ig gene rearrangement indicated that all of the
lymphoma samples were monoclonal or possibly oligoclonal
(Fig. 3). Hybridization with the PJ11 probe to samples from
lineage 3 revealed the standard 6.6-kb BamHI fragment rep-
resenting the unrearranged heavy chain allele and an addi-
tional 23-kb fragment that also hybridized to the LMP1 probe
(data not shown). Thus, all tissues from lineage 3 contained
two genomic fragments with LMP1 integrated in close prox-
imity to the IgH sequences. Ig gene rearrangement was
detected in all tissue samples with lymphoma, and in some
lymphoma samples, multiple rearranged bands could be de-
tected. In a lymphoma from lineage 9 (Fig. 3, lane 4) two
rearranged alleles were detected. This finding may represent a
clonal lymphoma with a rearrangement of both Ig alleles or
could represent a biclonal lymphoma. An example of lym-
phoma that developed in lineage 3 had three detectable
rearranged alleles, which would also suggest the proliferation
of more than one clone (Fig. 3, lane 2). Ig gene rearrangement
was detected in all tissue samples with lymphoma and was also
detected in the hyperplastic nodes, lymphoid infiltrates, and
some normal spleens (Fig. 3). The detection of clonal JH
rearrangement not only confirms the B cell origin of tumors
but also indicates that there can be clonal expansion without
histologic evidence of pathology.
The expression of LMP1 correlated with the detection of
clonality and lymphoma involvement. In the normal spleens
that were LMP1 positive, Ig rearrangement was detected in
57% of the samples but was detected in only 15% of normal
spleens that lacked the expression of LMP1. In animals with
lymphoma, the expression of LMP1 was detected only in tissue
samples with evidence of lymphoma and not in uninvolved
organs (Fig. 4A). In the animal designated A, LMP1 was
expressed in the hilar lymph node and spleen that had lym-
phoma but not in the skin or kidney. In animal B, LMP1 was
detected in the mesenteric lymph node, which contained
lymphoma, but not in the uninvolved, normal spleen. Similarly,
in animal C, the lymphoma tissue in the lung sample contained
LMP1, but LMP1 was not detected in the normal spleen of this
animal. Ig gene rearrangement correlated with detection of
LMP1 and identification of lymphoma (Fig. 4B).
Oncogene Expression. LMP1 has profound effects on cel-
lular gene expression through the activation of NF-kB and the
TRAF pathway (2, 6, 7, 11). LMP1 induces expression of B
lymphocyte activation markers and antiapoptotic molecules
such as Bcl-2, Mcl-1, and A20 (4–6, 27, 28). In vivo, bcl-2 and
c-myc are expressed at high levels in EBV-infected tumors
(29), suggesting that the activation of these genes is an
important consequence of EBV infection. Many of these
genes, including c-myc and A20, have been shown to be
regulated by NF-kB transcription factors (5, 30).
To determine whether these genes contributed to the de-
velopment of lymphoma in LMP1-induced transgenic tumors,
expression of A20, Bcl-2, and c-Myc was detected by immu-
noblot analysis. LMP1-positive lymphoma samples were com-
pared with known positive controls and lymphoma samples
that developed in LMP1-negative transgenic littermates. A20
is an unusual zinc finger containing protein that has been
shown recently to interact with TRAF2 (31) and to inhibit
specifically p53-mediated apoptosis (6). A cell line in which
A20 is expressed at high levels under the control of the human
cytomegalovirus immediate early promoter (H1299-A20) and
the A20-negative parental line were used as controls for
specificity of detection (6). A20 was found to be expressed at
high levels in all of the LMP1-positive transgenic lymphomas
but was not detected in the nontransgenic lymphoma samples
(Fig. 5). Similarly, high levels of Bcl-2 were detected in all
LMP1-positive lymphoma samples, but not in nontransgenic
lymphoma tissues. The Bcl-2 peptide specific for the antisera
effectively blocked this detection. Although the expression of
c-Myc was more variable, this protein was also expressed at
elevated levels in LMP1-induced lymphomas but at low levels
in nontransgenic lymphomas (Fig. 5). c-Myc was detected at
high levels in the known positive HL60 line but was not
FIG. 3. Transgenic lymphomas and lymphoid hyperplasia are
clonal. Southern blots were prepared with DNA from samples of
lymphoma, hyperplasia, or normal spleens and hybridized to a PJ11
probe representing the JH region of the heavy chain locus. ‘‘Normal
spleen’’ is a nontransgenic control spleen with the genomic 6.6-kb
EcoRI fragment. The upper genomic band (23 kb) in mice of lineage
3 is caused by the integration of the transgene into the heavy chain
locus in this lineage (lanes 1, 2, 3, 6, 9, and 10). Lanes 7, 8, 11, and 13
are from lineage 6. Lanes 4, 5, and 12 are from lineage 9.
FIG. 4. Expression of LMP1 correlates with IgH gene rearrange-
ment and lymphoma detection. (A) Immunoblots were prepared with
protein lysates from lymphoma samples and control tissues from three
mice and the B95–8 cell line. Mouse A had lymphoma in hilar LN
(lymph nodes) and the spleen, but not the skin and kidney. Mouse B
had lymphoma in the mesenteric LN but not in the spleen. Mouse C
had lymphoma in the lungs but not the spleen. ‘‘Normal spleen’’ was
a spleen from a nontransgenic control mouse. (B) IgH gene rear-
rangement. Southern blots were hybridized to the PJ11 probe and
showed the correlation of the lymphoma phenotype in the organs
described in A with clonal rearrangement. In mouse A, gene rear-
rangement was analyzed and detected only in the spleen. All three
mice were from lineage 3, which contained two genomic bands. The
upper band (23 kb) resulted from the integration of the transgene into
the heavy chain locus.
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detected in the negative HT1080 line. The absence of expres-
sion of any of these genes in the lymphomas that developed
spontaneously in the negative littermates suggests that other
growth-stimulating pathways have been activated in these
tumors. However, the consistent detection of elevated expres-
sion of A20, Bcl-2, and c-Myc in the LMP1 lymphomas
suggests that induction of their expression is an important
component of LMP1-induced lymphomagenesis.
DISCUSSION
Transgenic mice are a powerful tool for determining the
effects of the expression of specific genes in specific tissues in
a living animal (19). Many genes that have been identified as
potential oncogenes as partners in chromosomal transloca-
tions or by retroviral acquisition have been proven to be
oncogenic in transgenic models. Studies in transgenic mice of
viral oncogenes such as simian virus 40 large T antigen have
identified critical cellular pathways that are affected by the
expression of the viral genes (32, 33). Similar studies for the
human tumor virus EBV are more complex, because multiple
viral genes are expressed in EBV-transformed lymphoid cell
lines and in EBV-associated tumors, and several viral proteins
contribute to the transformed and tumorigenic phenotype.
Several studies have analyzed EBV genes in transgenic mice;
however, in most cases expression was restricted to unusual
tissues. The EBNA2 protein is essential for transformation and
is thought to represent a constitutively activated member of the
Notch signaling pathway (34, 35). The expression of EBNA2
under the control of the simian virus 40 early promoter and
enhancer fused to the lymphoid-specific EBV promoter within
BamHI W resulted in formation of renal adenocarcinomas
(36). Although EBNA2 mRNA could be detected in most
tissues, the protein was detected only at low levels in some
tubule cells. This finding suggested that the unique pathology
reflected expression that actually was restricted to kidney cells.
In contrast, the expression of the EBV leader protein induced
heart failure but did not induce tumors (37). A single study has
succeeded in expressing an EBV protein in lymphocytes. Two
lineages that express EBNA1 under the control of the polyoma
early promoter and the heavy chain enhancer have an in-
creased incidence of the development of lymphoma in elderly
mice (38). Surprisingly, EBNA1 was expressed in all mice at all
ages and was found at equivalent levels in normal and tumor
tissues from these mice.
The effect of the expression of LMP1 has been evaluated in
transgenic mice where LMP1 was expressed under the control
of the polyoma early promoter and enhancer (39). The ex-
pression of LMP1 induced epidermal hyperplasia with altered
keratin gene expression. Replacement of the polyoma en-
hancer with IgH enhancer resulted in embryonic lethality with
epidermal hyperplasia. In these mice, LMP1 could be detected
only in the skin in both polyoma and Ig enhancer transgenes.
Many studies have revealed toxicity associated with high levels
of expression of LMP1, and the high level of lethality in
transgenic mice likely reflects this toxicity (40).
In the IgH LMP1-transgenic lineages, the EBV gene is
successfully targeted to the lymphoid compartment of trans-
genic mice. The increased detection of LMP1 in normal
spleens in aging mice may reflect the promoter activity in
activated B cells and suggests that other events contribute to
the activation of the promoter or the survival of B cells that
express LMP1. However, whatever events contribute to the
expression of LMP1, it correlates well with pathology. In
normal spleens in which LMP1 is detected, LMP1 is expressed
at very low levels, perhaps reflecting occasional expression in
a subset of cells. The detection of clonal proliferation in
normal spleens may reflect the growth of these LMP1-
expressing cells. In contrast, in lymphoma tissue, LMP1 is
apparently expressed in most cells at levels equivalent to the
level in transformed B cells. Although the follicular center-cell
phenotype of the transgenic lymphomas is quite distinct from
EBV-positive lymphomas, this distinct pathology likely re-
f lects the mouse strain. Studies have shown that the same
transgene results in distinctive lymphomas dependent on the
mouse background (41).
Similar studies targeting the expression of cellular onco-
genes to B cells have had striking effects on B cell maturation
and lymphoma development. Ig-enhancer-regulated c-myc
transgenic mice have greatly enlarged spleens, with polyclonal
pre-B cell hyperplasia in young animals with 80% developing
lymphoma by 14 weeks of age (42). In contrast, Ig-enhancer
bcl-2 transgenic mice developed splenic hyperplasia, but only
11% of animals over 1 year old developed lymphoma (43). In
dually transgenic mice, c-myc and bcl-2 are complementary,
with mice developing lymphoma by 5–6 weeks of age (44).
Although the LMP1 transgenic animals have elevated expres-
sion of both c-myc and bcl-2, the phenotype is less severe than
that of deregulated c-myc but has greater malignant potential
than deregulated bcl-2. These differences in malignant poten-
tial may reflect the fact that these genes are still regulated
through their natural promoters and that LMP1 has activated
their expression through pathways operative in normal B cells.
However, the significantly elevated incidence of lymphoma
in these mice indicates that the constitutive activation of the
TNFR family’s signaling pathways is oncogenic. The data
presented in this study suggest that NF-kB is activated in the
lymphomas, because two genes, A20 gene and c-myc, thought
to be regulated by NF-kB (5, 30), are expressed. LMP1 has
been shown to induce A20 expression by activating NF-kB,
thereby blocking p53-mediated apoptosis (5, 6). Stimulation of
a murine B lymphoma cell line with CD40L, a condition
probably comparable to activation by LMP1, induces and
sustains NF-kB binding to the sites known for transcriptional
regulation of c-myc, thereby maintaining c-myc RNA levels
FIG. 5. A20, Bcl-2, and c-Myc are expressed at elevated levels in
transgenic lymphoma. Immunoblots were prepared with 200 mg total
protein lysates from lymphomas that developed in nontransgenic
littermates and transgenic lymphoma tissues and reacted with mouse
monoclonal anti-A20, rabbit polyclonal anti-Bcl-2, and rabbit poly-
clonal anti-c-Myc.
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and rescuing the cells from anti-surface-IgM-induced apopto-
sis (30). LMP1 has also been shown to up-regulate bcl-2
expression in B lymphocytes and thus protect the cells from
apoptosis (4). The elevated levels of A20, Bcl-2, and c-Myc
detected in the transgenic lymphomas suggest that the expres-
sion of their genes is a critical component in LMP1-mediated
lymphomagenesis. However, the advanced age of the mice that
developed tumors and the clonality of the tumors suggest that
other genes or pathways that complement the pathway(s)
activated by LMP1 must also become activated and contribute
to the development of lymphoma. In EBV-transformed lym-
phocytes, similarly complementary pathways may be activated
by other viral gene products.
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